AbCellera Biologics (ABCL) EBIT (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly EBIT came in at -$57.5 million in Q1 2026, up 8.2% YoY from -$53.2 million in Q1 2025, and down 101.24% on a QoQ basis from -$28.6 million in Q4 2025.
AbCellera Biologics (ABCL) EBIT (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of EBIT data on file, last reported at -$57.5 million in Q1 2026.
- Quarterly EBIT rose 8.2% year-over-year to -$57.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$212.0 million (up 34.28% YoY) and the FY2025 annual result came in at -$217.1 million, up 31.03% from the prior year.
- EBIT slipped to -$57.5 million in Q1 2026, from -$28.6 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $225.0 million in Q1 2022 to a low of -$93.7 million in Q3 2024.
- A 5-year average of -$35.9 million and a median of -$54.9 million in 2024 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT jumped 234.31% — and 2023, when it slumped 512.07%.
- Tracing ABCL's EBIT over 5 years: stood at -$37.8 million in 2022, then slumped by 74.85% to -$66.1 million in 2023, then declined by 10.15% to -$72.8 million in 2024, then soared by 60.71% to -$28.6 million in 2025, then slumped by 101.24% to -$57.5 million in 2026.
- The last three EBIT figures came in at -$57.5 million (Q1 2026), -$28.6 million (Q4 2025), and -$76.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | -62.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.78 Mn |
| Mar 31, 2026 | -57.52 Mn |
| Dec 31, 2025 | -28.58 Mn |
| Sep 30, 2025 | -76.28 Mn |
| Jun 30, 2025 | -49.59 Mn |
| Mar 31, 2025 | -62.66 Mn |
| Dec 31, 2024 | -72.76 Mn |
| Sep 30, 2024 | -93.66 Mn |
| Jun 30, 2024 | -93.45 Mn |
| Mar 31, 2024 | -54.89 Mn |
| Dec 31, 2023 | -66.05 Mn |
| Sep 30, 2023 | -54.89 Mn |
| Jun 30, 2023 | -51.39 Mn |
| Mar 31, 2023 | -64.87 Mn |
| Dec 31, 2022 | -37.78 Mn |
| Sep 30, 2022 | 37.74 Mn |
| Jun 30, 2022 | -8.40 Mn |
| Mar 31, 2022 | 224.95 Mn |
| Dec 31, 2021 | 81.55 Mn |
| Sep 30, 2021 | -28.10 Mn |